Avidity Biosciences Inc (RNAM)

Feb 26, 2026, 4:02 PM EST - 6 hours ago

Avidity Biosciences Announces Multiple Upcoming Presentations at 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Feb 23, 2026, 8:00 AM EST - 3 days ago

Avidity Biosciences Announces Intention to Adjourn and Reconvene Special Meeting of Stockholders

Feb 18, 2026, 5:00 PM EST - 8 days ago

The New England Journal of Medicine Publishes Results from Phase 1/2 MARINA® Trial of Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1

Feb 2, 2026, 9:44 PM EST - 24 days ago

Avidity Biosciences Announces Expected Record Date for Spin-Off

Jan 29, 2026, 10:30 PM EST - 27 days ago

Harbor Small Cap Growth Fund Q4 2025 Portfolio Performance

ABBV ABVX CVLT FIX FTAI GKOS GMAB

Jan 28, 2026, 4:15 PM EST - 4 weeks ago

Sonoma Pharmaceuticals Welcomes New Member of its Board of Directors and New Senior Vice President of Regulatory, Quality and Product Development

SNOA

Jan 15, 2026, 11:35 AM EST - 6 weeks ago

Pharma sector doubles down on AI amid hopes of slashing costs, timelines

AZN GEHC LLY

Dec 16, 2025, 8:30 AM EST - 2 months ago

Top 2 Health Care Stocks That May Keep You Up At Night In December

HSIC

Nov 20, 2025, 3:45 PM EST - 3 months ago

These 15 stocks are still showing momentum — and a market-beating edge

BE CIEN CRDO GH INSM LITE MP

Nov 19, 2025, 9:13 AM EST - 3 months ago

Avidity Biosciences Announces U.S. Managed Access Program (MAP) for Investigational Therapy del-zota in DMD44

Nov 10, 2025, 4:05 PM EST - 3 months ago

Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights

Oct 28, 2025, 5:13 PM EDT - 4 months ago

3 Investable Laggards In An Overbought Market

AVDL BMY ETNB MRUS MTSR NVS PAGP

Oct 27, 2025, 8:05 PM EDT - 4 months ago

Avidity Biosciences Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Avidity Biosciences, Inc. - RNA

Oct 27, 2025, 2:52 PM EDT - 4 months ago

Avidity Biosciences Soars After $72 Per Share Novartis Takeover

NVS

Oct 27, 2025, 12:31 PM EDT - 4 months ago

Why Avidity Biosciences And Dyne Therapeutics Stocks Soared 40% Monday

Oct 27, 2025, 10:22 AM EDT - 4 months ago

Is it too late to buy Avidity stock after Novartis deal?

Oct 27, 2025, 8:16 AM EDT - 4 months ago

Trump's trade deals, Novartis acquires Avidity, Taco Bell's beverage push and more in Morning Squawk

NVS

Oct 27, 2025, 6:54 AM EDT - 4 months ago

Wall Street Breakfast Podcast: Novartis Puts $12B On The Table

HSBC NVS

Oct 27, 2025, 6:29 AM EDT - 4 months ago

Novartis shares slip, Avidity soars after $12 billion biotech deal

NVS

Oct 27, 2025, 4:59 AM EDT - 4 months ago

Novartis Agrees $12 Billion Biotech Deal for Avidity

NVS

Oct 26, 2025, 5:33 PM EDT - 4 months ago

Novartis Agrees to Acquire Avidity Biosciences for $12 Billion

NVS

Oct 26, 2025, 3:46 PM EDT - 4 months ago

Novartis to acquire Avidity Biosciences for about $12B

NVS

Oct 26, 2025, 3:29 PM EDT - 4 months ago

Novartis Deal Values Avidity Biosciences At $12 Billion

NVS

Oct 26, 2025, 1:07 PM EDT - 4 months ago

Novartis to acquire Avidity Biosciences for $12 billion

NVS

Oct 26, 2025, 1:07 PM EDT - 4 months ago

Avidity Biosciences Enters into Agreement to be Acquired by Novartis AG

NVS

Oct 26, 2025, 1:00 PM EDT - 4 months ago

Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience pipeline

NVS

Oct 26, 2025, 12:26 PM EDT - 4 months ago

Novartis is in talks to buy U.S. biotech firm Avidity Biosciences for more than $70 a share, Bloomberg News reports

NVS

Oct 26, 2025, 11:09 AM EDT - 4 months ago

Novartis nears $70-plus per share deal to acquire Avidity Biosciences, Bloomberg News reports

NVS

Oct 16, 2025, 9:00 AM EDT - 4 months ago

Avidity Biosciences to Participate in Upcoming Investor Conference

Oct 13, 2025, 9:00 AM EDT - 4 months ago

Avidity Biosciences Announces Positive Pre-BLA Meeting with U.S. FDA for del-zota in DMD44 with a Submission Planned for Q1 2026

Oct 6, 2025, 9:00 AM EDT - 5 months ago

Avidity Biosciences to Present Data from EXPLORE44® Clinical Development Program of Del-Zota in DMD44 at 30th Annual Congress of the World Muscle Society

Sep 15, 2025, 4:01 PM EDT - 5 months ago

Avidity Biosciences, Inc. Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Sep 11, 2025, 7:56 PM EDT - 6 months ago

Avidity Biosciences Announces Pricing of Upsized Public Offering of Common Stock

Sep 11, 2025, 2:36 PM EDT - 6 months ago

Avidity Biosciences: Maintaining 'Strong Buy' Rating Based On Accelerated Approval Filing For Del-Zota

Sep 11, 2025, 8:08 AM EDT - 6 months ago

Lovesac, Avidity Biosciences, Veritone And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

LOVE VERI

Sep 10, 2025, 5:40 PM EDT - 6 months ago

Avidity Biosciences, Inc. (RNA) Discusses On Redefining The Treatment Of Duchenne Muscular Dystrophy (Transcript)

Sep 10, 2025, 4:01 PM EDT - 6 months ago

Avidity Biosciences Announces Proposed Public Offering of Common Stock

Sep 10, 2025, 7:00 AM EDT - 6 months ago

Avidity Biosciences' Del-zota Demonstrated Reversal of Disease Progression Across Key Functional Endpoints in EXPLORE44® and EXPLORE44-OLE™ Phase 1/2 Trial in People Living with DMD44

Sep 8, 2025, 4:45 PM EDT - 6 months ago

Avidity Biosciences, Inc. (RNA) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Sep 7, 2025, 10:15 PM EDT - 6 months ago

Avidity Biosciences, Inc. (RNA) Presents At Cantor Global Healthcare Conference 2025 Transcript

Sep 5, 2025, 5:37 AM EDT - 6 months ago

Avidity Biosciences, Inc. (RNA) Presents at Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Aug 27, 2025, 9:00 AM EDT - 6 months ago

Avidity Biosciences to Participate in Upcoming Investor Conferences

Aug 7, 2025, 4:05 PM EDT - 7 months ago

Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights

Aug 6, 2025, 11:41 AM EDT - 7 months ago

Novartis weighs deal for biotech Avidity Biosciences, FT reports

NVS

Jul 28, 2025, 9:00 AM EDT - 7 months ago

Avidity Biosciences Announces Completion of Enrollment for HARBOR™, the First Global Phase 3 Trial of Delpacibart Etedesiran (del-desiran) for Treatment of DM1 and Provides Guidance on Regulatory Submission

Jul 23, 2025, 9:00 AM EDT - 7 months ago

Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Zotadirsen (del-zota) for the Treatment of DMD in People with Mutations Amenable to Exon 44 Skipping